PXBioVisioN

Executive Summary

PXBioVisioN is a German bioanalytical Contract Research Organization (CRO) specializing in peptide biomarker development and peptidomics. Founded in 2017 and based in Munich with laboratory operations in Hannover, the company provides mass spectrometry-based analytical services to identify and quantify peptides in complex biological samples. Its offerings support pharmaceutical clients in drug discovery and clinical proof-of-concept stages, addressing the growing demand for precision biomarker analysis in ophthalmology and other therapeutic areas. As a privately held CRO, PXBioVisioN benefits from the increasing outsourcing of specialized bioanalytical services by biopharma firms, though its revenue base remains dependent on project-based contracts. The company's expertise in peptidomics positions it well in a niche but expanding market, but its lack of proprietary product pipeline limits potential for exponential growth. Overall, PXBioVisioN represents a stable, service-oriented business with moderate growth prospects tied to industry R&D spending trends.

Upcoming Catalysts (preview)

• Q2 2026Major pharma partnership or multi-year contract award55% success
• Q3 2026Expansion of laboratory capacity or new service line launch45% success
• Q4 2026Achievement of ISO/IEC 17025 accreditation for enhanced credibility60% success